News Image

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

Provided By GlobeNewswire

Last update: May 13, 2025

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”) announced today that its NAMkind™ platform for intestinal efficacy prediction was recognized with a blue ribbon “Poster of Distinction” award at the Digestive Disease Week Conference (San Diego, CA, May 2-6, 2025). The work describes developing a robust, multicellular in vitro model that closely mirrors human intestinal biology, paving the way for safer and more effective therapies for inflammatory bowel disease (IBD).

Read more at globenewswire.com

VIVOSIM LABS INC

NASDAQ:VIVS (9/3/2025, 8:00:02 PM)

Premarket: 2.55 +0.03 (+1.19%)

2.52

+0.18 (+7.69%)



Find more stocks in the Stock Screener

VIVS Latest News and Analysis

Follow ChartMill for more